

Influenza (2016 – 2017)

Vaccine	Influenza Types	Recommended Age	Dosage
Inactivated Influenza Vaccine (IIV3, IIV4)	Trivalent (IIV3): <ul style="list-style-type: none"> • A/California/7/2009 (H1N1)- like virus • A/Hong Kong/4801/2014 (H3N2)-like virus • B/Brisbane/60/2008-like virus (Victoria lineage) Quadrivalent (IIV4): <ul style="list-style-type: none"> • Same components as trivalent vaccine above; and a B/Phuket/3073/2013-like virus (Yamagata lineage) 	≥6 months (Age requirements vary by vaccine)	0.25 mL IM [‡] (6-35 months) 0.5 mL IM (≥36 months) 0.1 mL ID (18 – 64 years)
Live Attenuated Influenza Vaccine (LAIV4)^{**}	Quadrivalent (please see components above)	2 – 49 years (healthy, non-pregnant)	0.2 mL intranasal (0.1 mL in each nostril)
Recombinant Hemagglutinin Influenza Vaccine (RIV3)	Trivalent (please see components above)	≥18 years	0.5 mL IM
Cell Culture-based Influenza Vaccine (ccIIV3)	Trivalent (please see components above)	≥18 years	0.5 mL IM
Cell Culture-based Influenza Vaccine (ccIIV4)	Quadrivalent (please see components above)	≥4 years	0.5 mL IM
Adjuvanted Inactivated Influenza Vaccine (aIIV3)	Trivalent (please see components above)	≥65 years	0.5 mL IM

General Recommendations:

- All persons aged ≥6 months should receive an annual influenza vaccination unless contraindicated.
- Children aged 6 months through 8 years receiving influenza vaccine for the first time should receive their first dose as soon as possible after vaccine becomes available, and the second dose ≥4 weeks later (See Figure 2).
- [‡]Per California Law, pregnant women and children under 3 years should receive preservative-free influenza vaccine.
- Observe all patients with history of egg allergy for 15 minutes after vaccination to decrease the risk for injury should they experience syncope (See Figure 1).
- ^{**}Due to low vaccine efficacy, **LAIV is not recommended during the 2016 – 17 influenza season.**

Persons at Increased Risk for Medical Complications Attributable to Influenza:

- Persons aged 6 through 59 months.
- Aged ≥50 years.
- Persons who have chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).
- Persons who are immunosuppressed (including immunosuppression caused by medications or by HIV).
- Pregnant women or women who will be pregnant during the influenza season.
- Children and adolescents 6 months-18 years who are receiving long-term aspirin therapy.
- Residents of nursing homes and other chronic-care facilities.
- American Indians/Alaska Natives.
- Morbidly obese (BMI ≥40).

Precautions

IIV, ccIIV3, aIIV3, and RIV

- Development of Guillain-Barré within 6 weeks of receiving a flu vaccine previously.
- Moderate to severe illness with or without a fever.


LAIV (not recommended for 2016-17)

- Moderate or severe illness with or without fever.
- History of Guillain – Barré within 6 weeks of receiving influenza vaccine.
- Asthma in persons ≥5 years.
- Other underlying medical conditions that might predispose to complications after influenza infection (e.g. chronic pulmonary, cardiovascular (except hypertension), renal, hepatic, neurologic, hematologic, or, metabolic disorders, including diabetes).

IP-B71-FLU-V3 (08/25/16)



Figure 1: Recommendations regarding influenza vaccination for persons who report allergy to eggs: 2016-17 Influenza Season[§]



[§]Adapted from 2015-16 ACIP Influenza Vaccine Recommendations for Persons Who Report Allergy to Eggs.

^{§§}Persons with a history of severe allergic reaction to eggs (i.e. any symptoms other than hives) should be vaccinated in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices), under the supervision of a health care provider who is able to recognize and manage severe allergic conditions.

Contraindications
IIV, ccIIV3, aIIV3, and RIV3

- Severe reaction to a flu vaccination in the past, **including egg protein** (i.e. anaphylaxis) (**IIV & ccIIV3**).
- History of severe allergic reaction to any vaccine component (**RIV3**).
- Children <6 months of age.
- Latex allergies (Seqirus products).

LAIV (not recommended for 2016-17)

- History of severe allergic reaction to any component to the vaccine or after a previous dose of any flu vaccine.
- Children 2 - 17 years receiving aspirin or aspirin – containing products.
- Persons who are immunosuppressed (including immunosuppression caused by medications or HIV).
- Pregnant women.
- Persons with a history of egg allergy
- Children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma within the last 12 months.

Adverse Reactions
IIV, ccIIV3, aIIV3, and RIV3

- **Injection site:** pain redness, swelling.
- **Systemic:** fever, aches, headache, fatigue (usually begin soon after the shot and last 1-2 days).


LAIV (not recommended for 2016-17)
Children and adolescents aged 2-17 years of age have reported:

- Runny nose, nasal congestion or cough.
- Fever, headache and muscle aches.
- Wheezing.
- Abdominal pain or occasional vomiting or diarrhea.

Some adults 18-49 years of age have reported:

- Runny nose or nasal congestion.
- Sore throat.
- Cough, chills, tiredness/weakness.
- Headache.

Figure 2: Influenza vaccine dosing algorithm for children 6 months - 8 years ACIP- United States, 2016-17 Influenza Season



* The two doses need not have been received during the same season or consecutive seasons.